Search results
Results from the WOW.Com Content Network
Developments in targeted drug delivery to tumors have provided the groundwork for the burgeoning field of targeted drug delivery to cardiac tissue. [5] Recent developments have shown that there are different endothelial surfaces in tumors, which has led to the concept of endothelial cell adhesion molecule-mediated targeted drug delivery to tumors.
Liposomes were first reported as drug-delivery vehicles in the 1960s and are biomimetic nanosomes composed of phospholipid bilayers. Due to their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs, liposomes are a popular choice for pH-responsive tumor-targeted drug delivery.
Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells. Many targeted therapies are examples of immunotherapy (using immune mechanisms for therapeutic goals) developed by the field of cancer immunology. Thus, as immunomodulators, they are one type of biological response modifiers.
There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. [15] One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. [15]
Schematic structure of an antibody–drug conjugate (ADC) Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were ...
Targeted drug delivery systems facilitate the selective delivery of therapeutic agents to specific disease sites while minimizing off-target effects. These systems employ strategies, such as nanoparticles, liposomes, and micelles, to encapsulate drugs and enhance their stability, solubility, and bioavailability. [15]
Overall, microdroplet-based drug delivery systems show great promise for revolutionizing medicine with significant potential for targeted drug delivery. Limitations Nevertheless, it is essential to note some common challenges associated with microdroplet-based drug delivery systems, including their biocompatibility, toxicity, and scalability. [2]
While some drugs and radioimaging agents are delivered to cells as folate conjugates in a one-to-one folate-to-conjugate ratio, folate-targeted liposomes allow for the delivery of larger amounts of chemotherapeutic agents. [12] In this technique, drug particles are enveloped in a plasma membrane-bound vesicle.